# Amgen CDR (CAD Hedged) (AMGN.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$34.09, market value C$334.8 billion.

## Valuation
- **P/E (trailing): 27.1×** (5-yr avg 31.3×, 3-yr avg 31.3×). Amgen CDR (CAD Hedged) trades at 27.1× trailing earnings, close to its own five-year average of 31.3×. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 8.8×**. Each dollar of revenue is priced at 8.8×.
- **Price / book: 38.7×**. The shares trade at 38.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 21.6×**. Enterprise value is 21.6× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 3.0%** (5-yr avg 3.4%). Free cash flow equals 3.0% of the market value, in line with its five-year average of 3.4%.
- **Earnings yield: 3.7%**. The inverse of the P/E: 3.7% of the price is earned each year.

## Profitability
- **Gross margin: 69.5%**. Amgen CDR (CAD Hedged) keeps 69.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 30.0%**. 30.0% of revenue is left after running the business, an exceptional level.
- **Net margin: 21.0%**. 21.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 89.1%**. A 89.1% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 17.9%**. Return on all capital, debt included, is 17.9%: comfortably above what that capital costs.
- **Return on assets: 9.7%**. Each dollar of assets produces 9.7% of profit.

## Growth
- **Revenue growth (1 yr): 10.0%** (3-yr 11.8%/yr). Revenue grew 10.0% over the last year.
- **EPS growth (1 yr): 88.2%** (3-yr 5.5%/yr). Earnings per share rose 88.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -2.7%/yr**. Free cash flow has compounded at -2.7% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 6.31**. Debt is 6.31 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 2.6×**. It would take 2.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 4.3×**. Operating profit covers interest 4.3× over, a safe margin.
- **Current ratio: 1.14** (quick 0.90). Current assets cover the next year's liabilities 1.14 times.
- **Altman Z-score: 3.39**. A Z-score of 3.39 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Amgen CDR (CAD Hedged) does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -2.6%** (42.3% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 72**. An RSI of 72 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.47** (volatility 30%). Beta of 0.47 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AMGN.TO · Page: https://foliofundamentals.com/stocks/amgn.to

Not investment advice.